Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

PNAS 102 (3): 862-867

Copyright © 2005 by the National Academy of Sciences.


NEUROSCIENCE

A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain

Hannelore Ehrenreich *, {dagger}, Martin Hasselblatt *, Friederike Knerlich *, Nico von Ahsen {ddagger}, Sonja Jacob *, Swetlana Sperling *, Helge Woldt *, Katalin Vehmeyer §, Klaus-Armin Nave *, and Anna-Leena Sirén *

*Max Planck Institute of Experimental Medicine and {ddagger}Departments of Clinical Chemistry and §Hematology and Oncology, Georg-August University, 37075 Goettingen, Germany

Edited by Anthony Cerami, The Kenneth S. Warren Institute, Kitchawan, NY, and approved December 2, 2004

Received for publication August 15, 2004.

Abstract: Central nervous and hematopoietic systems share developmental features. We report that thrombopoietin (TPO), a stimulator of platelet formation, acts in the brain as a counterpart of erythropoietin (EPO), a hematopoietic growth factor with neuroprotective properties. TPO is most prominent in postnatal brain, whereas EPO is abundant in embryonic brain and decreases postnatally. Upon hypoxia, EPO and its receptor are rapidly reexpressed, whereas neuronal TPO and its receptor are down-regulated. Unexpectedly, TPO is strongly proapoptotic in the brain, causing death of newly generated neurons through the Ras-extracellular signal-regulated kinase 1/2 pathway. This effect is not only inhibited by EPO but also by neurotrophins. We suggest that the proapoptotic function of TPO helps to select for neurons that have acquired target-derived neurotrophic support.

Key Words: astrocytes • erythropoietin • neurons • differentiation • development


Author contributions: A.-L.S. designed research; K.V. and A.-L.S. performed research; K.V. and A.-L.S. contributed new reagents/analytic tools; A.-L.S. analyzed data; and K.-A.N. and A.-L.S. wrote the paper.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: En, embryonic day n; EPO, erythropoietin; EPOR, EPO receptor; ERK, extracellular signal-regulated kinase; ISOL, in situ oligo ligation; PI3K, phosphatidylinositol 3-kinase; Pn, postnatal day n; TPO, thrombopoietin; TPOR, TPO receptor.

{dagger} To whom correspondence should be addressed. E-mail: ehrenreich{at}em.mpg.de.

© 2005 by The National Academy of Sciences of the USA


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Do we know when to treat neonatal thrombocytopaenia?.
V. Venkatesh, A. E. Curley, P. Clarke, T. Watts, and S. J. Stanworth (2013)
Arch. Dis. Child. Fetal Neonatal Ed. 98, F380-F382
   Full Text »    PDF »
Effect and mechanism of erythropoietin on mesenchymal stem cell proliferation in vitro under the acute kidney injury microenvironment.
N. Liu, J. Tian, W. Wang, J. Cheng, D. Hu, and J. Zhang (2011)
Experimental Biology and Medicine 236, 1093-1099
   Abstract »    Full Text »    PDF »
Thrombopoietin Contributes to Neuronal Damage in Experimental Bacterial Meningitis.
O. Hoffmann, O. Rung, A.-R. Im, D. Freyer, J. Zhang, J. Held, W. Stenzel, and C. Dame (2011)
Infect. Immun. 79, 928-936
   Abstract »    Full Text »    PDF »
Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons.
P. E. Sanchez, R. P. Fares, J.-J. Risso, C. Bonnet, S. Bouvard, M. Le-Cavorsin, B. Georges, C. Moulin, A. Belmeguenai, J. Bodennec, et al. (2009)
PNAS 106, 9848-9853
   Abstract »    Full Text »    PDF »
Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis..
C. Bartels, K. Spate, H. Krampe, and H. Ehrenreich (2008)
Therapeutic Advances in Neurological Disorders 1, 193-206
   Abstract »    PDF »
An Approach to Using Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants.
J.-C. Fauchere, C. Dame, R. Vonthein, B. Koller, S. Arri, M. Wolf, and H. U. Bucher (2008)
Pediatrics 122, 375-382
   Abstract »    Full Text »    PDF »
Hemoglobin-Independent Organ Protection by EPO in Humans: Amelioration of Cognitive Loss in Chronic Schizophrenia.
H. Ehrenreich, D. Hinze-Selch, S. Stawicki, C. Aust, S. Knolle-Veentjer, S. Wilms, G. Heinz, S. Erdag, H. Jahn, D. Degner, et al. (2007)
J. Am. Soc. Nephrol. 18, 3-6
   Abstract »    Full Text »    PDF »
Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin.
A.-L. Siren, K. Radyushkin, S. Boretius, D. Kammer, C.-C. Riechers, O. Natt, D. Sargin, T. Watanabe, S. Sperling, T. Michaelis, et al. (2006)
Brain 129, 480-489
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882